Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a stable growth in revenue and net profit for H1 2024, with revenue reaching 385 million yuan, up 5.21% year-on-year, and net profit attributable to the parent company at 89 million yuan, up 11.04% year-on-year [2] - The lens business showed resilience, supporting an increase in the company's gross margin to 59.40%, up 2.72 percentage points from the same period last year [2] - The focus on product strategy led to rapid growth in key products, with the PMC Ultra Bright series seeing a revenue increase of 58.82% year-on-year [2] - The "Easy Control" series for myopia prevention achieved sales of 76 million yuan in H1 2024, up 38.86% year-on-year [2] - The company entered into an exclusive cooperation agreement with Leica in the lens field, enhancing collaboration in brand operation, technology development, and market promotion [2] Financial Forecasts and Valuation - The company adjusted its net profit forecasts for 2024-2026, now estimating 1.76 billion yuan, 1.95 billion yuan, and 2.14 billion yuan respectively, with the latest closing price corresponding to P/E ratios of 32, 28, and 26 times for 2024-2026 [3] - The projected earnings per share (EPS) for 2024 is 0.87 yuan, with a P/E ratio of 31.56 [1][3]

Investment Rating - Buy (Maintained) [1] Core Views - The company's revenue and net profit attributable to the parent company showed steady growth in H1 2024, with revenue reaching 385 million yuan, a year-on-year increase of 5.21%, and net profit attributable to the parent company reaching 89 million yuan, a year-on-year increase of 11.04% [2] - The lens business demonstrated resilience, supporting the company's gross margin growth, with a gross margin of 59.40% in H1 2024, an increase of 2.72 percentage points year-on-year [2] - The company's product focus strategy has driven rapid growth in key products, with the PMC Ultra-Bright series growing 58.82% year-on-year and the 1.71 series growing 24.40% year-on-year in H1 2024 [2] - The "Easy Control" series of myopia prevention products continued to grow rapidly, with sales reaching 76 million yuan in H1 2024, a year-on-year increase of 38.86% [2] - The company entered into an exclusive cooperation agreement with Leica in the lens field, covering brand operations, technology R&D, precision imaging, optical design, precision manufacturing, and market promotion [2] Financial Performance - The company's operating income in 2024 is expected to reach 822.06 million yuan, a year-on-year increase of 9.79%, with net profit attributable to the parent company expected to reach 175.61 million yuan, a year-on-year increase of 11.47% [1] - The company's EPS for 2024 is forecasted to be 0.87 yuan per share, with a P/E ratio of 31.56 times [1] - The company's gross margin for 2024 is expected to be 57.94%, with a net profit margin attributable to the parent company of 21.36% [9] Product and Market Performance - The "Easy Control Pro" product showed a 72% effectiveness rate in delaying myopia progression over 24 months, with 97% of users adapting to the lenses within one day [2] - The company's lens business revenue reached 320 million yuan in H1 2024, a year-on-year increase of 12.08%, with a gross margin of 63.48%, an increase of 2.17 percentage points year-on-year [2] Strategic Developments - The company's cooperation with Leica is expected to enhance its brand and technological capabilities in the lens market [2] - The company's focus on key products and myopia prevention has driven significant growth in its core product lines [2]

明月镜片股份有限公司 2024 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 单位：元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算 | 2024 年期初占用 | 2024 用累计发生金额 | 年半年度占 | 2024 年半年度 占用资金的利 | 2024 半年度偿还 | 2024 | 年半年度期末 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 的关联关系 | 的会计科目 | 资金余额 | （不含利息） | | 息(如有) | 累计发生金额 | | 占用资金余额 | | | 控股股东、实际控制人及其 | | | | | | | | | | | 非经营性占用 | | 附属企业 | | | | | | | | | | | 非经营性占用 | | 小计 | 无 | | | | | | | | | | - | | 前控股股东、实际控制人及 | | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | ...

明月镜片股份有限公司 关于部分募投项目延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 明月镜片股份有限公司（以下简称"公司"）于 2024 年 8 月 20 日召开了第 二届董事会第十四次会议和第二届监事会第十四次会议，分别审议通过了《关于 部分募投项目延期的议案》，同意公司在募投项目实施主体、实施方式、建设内 容、募集资金投资用途及投资规模不发生变更的前提下，将"营销网络及产品展 示中心建设项目"的预定可使用状态时间相应调整。本次募投项目延期事项在董 事会的审批权限范围内，无需提交股东大会审议。现将有关情况公告如下： 一、募集资金基本情况 证券代码：301101 证券简称：明月镜片 公告编号：2024-028 三、本次部分募集资金投资项目延期的具体情况 根据募投项目的实施进度，经审慎分析和认真研究，为了维护全体股东和公 司的利益，在项目实施主体、实施方式、建设内容、募集资金投资用途及投资规 模都不发生变更的情况下，公司决定将募投项目"营销网络及产品展示中心建设 项目"进行延期。上述募投项目截至 2024 年 7 月 31 日的资金投入情况，及本次 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 385,020,343.87, representing a 5.21% increase compared to CNY 365,939,936.15 in the same period last year[11]. - The net profit attributable to shareholders for the first half of 2024 was CNY 88,966,730.67, an increase of 11.04% from CNY 80,121,334.97 in the previous year[11]. - The basic earnings per share for the first half of 2024 was CNY 0.4415, reflecting an increase of 11.04% compared to CNY 0.3976 in the previous year[11]. - The overall business gross margin for the first half of 2024 was 59.40%, an increase of 2.72 percentage points compared to the same period last year[22]. - The company's lens business grew by 13.98% year-on-year in the first half of 2024, despite external pressures, with the PMC Ultra Bright series revenue increasing by 58.82%[22]. - The company reported a net profit for the first half of 2024 of ¥94,041,806.31, compared to ¥86,922,150.50 in the previous year, representing an increase of 8.4%[106]. - The company achieved a gross profit margin of approximately 59.3% in the first half of 2024, compared to 56.5% in the same period of 2023[104]. Cash Flow and Financial Position - The net cash flow from operating activities decreased by 24.91% to CNY 71,021,733.53, down from CNY 94,584,559.32 in the same period last year[11]. - The net cash flow from financing activities decreased by 41.70% to -67,086,281.38 CNY, primarily due to an increase in dividend distribution[34]. - The cash and cash equivalents at the end of the period were CNY 124,973,977.75, a decrease from CNY 503,378,082.67 at the end of the first half of 2023[111]. - The company's cash and cash equivalents decreased to ¥403,195,873.35 from ¥953,307,795.82, representing a decline of approximately 57.7%[98]. - The total liabilities as of the end of the first half of 2024 were ¥118,105,839.46, compared to ¥113,175,604.01 at the end of the first half of 2023, reflecting an increase of 4.1%[105]. Investment and R&D - Research and development investment increased by 30.69% to ¥14,715,236.62, up from ¥11,259,749.75 in the previous year, indicating a strong focus on innovation[33]. - The company has maintained a strong commitment to research and development, holding numerous patents and being recognized as a high-tech enterprise in the optical lens industry[15]. - The company is actively pursuing new product development and technology advancements to enhance operational efficiency and market competitiveness[64]. Market Strategy and Product Development - The company has developed a comprehensive product line for myopia control lenses, with 24 SKUs covering various refractive indices and categories[16]. - A new partnership with Leica has been established to enhance high-end lens market offerings, focusing on technology development and optical design[16]. - The company launched a new blue light blocking lens product line in April 2024, expanding its product offerings to meet diverse consumer needs[16]. - The company has launched the "Good Doctor" brand in the medical channel, covering all age groups to meet diverse visual health needs[18]. - The company has established a network of tens of thousands of offline retail stores, focusing on direct sales, distribution, and medical channel collaboration, leading to sustained high sales growth[18]. Environmental Compliance and Sustainability - The company has received environmental approvals for various production projects, including a 10 million pairs per year optical equipment production project approved in May 2008 and a 30 million pieces production line upgrade approved in March 2023[60]. - The company achieved compliance with all pollutant discharge standards across its facilities, including air and water emissions[67]. - The company has set ambitious targets for reducing overall emissions by 20% over the next three years as part of its sustainability initiatives[64]. - The company reported a reduction in ammonia nitrogen (NH3-N) levels to 5.45 mg/Nm³, with an annual discharge of 0.46 tons, indicating improved wastewater treatment processes[62]. Shareholder Returns and Dividends - The company plans not to distribute cash dividends or issue bonus shares[2]. - The company distributed a cash dividend of CNY 3.00 per share, totaling CNY 60,219,785.40 (including tax), ensuring shareholder returns[72]. - The company has implemented a three-year shareholder dividend return plan (2024-2026) to enhance transparency and sustainability of profit distribution[72]. Risk Management - The company emphasizes the importance of risk factors in its operations and encourages investors to pay attention to investment risks[1]. - The company faces risks related to macroeconomic conditions that could negatively impact demand for its lens products if disposable income growth slows[52]. - The company acknowledges the risk that the benefits from fundraising projects may not meet expectations due to market changes affecting sales prices and production costs[55]. Corporate Governance - The company has not reported any changes in its registration status during the reporting period[10]. - There were no significant changes in the board of directors, supervisors, or senior management during the reporting period[58]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[74].

证券代码：301101 证券简称：明月镜片 公告编号：2024-027 明月镜片股份有限公司 2024 年半年度募集资金存放与使用情况专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》、《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求（2022 年修订）》等有关规定，现将明月镜片股份有限公司（以下简称"公 司"）2024 年半年度募集资金存放与使用情况说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意明月镜片股份有限公司首次公开发行 股票注册的批复》（证监许可〔2021〕3473 号）同意注册，公司获准首次公开发 行人民币普通股（A 股）股票 3,358.54 万股，每股面值 1 元，每股发行价格为 人民币 26.91 元，募集资金总额为人民币 903,783,114.00 元，扣除各类发行费 用后实际募集资金净额为人民币 792,923,877.64 元。上述募集资金到位情况经 立信会计师事务所 ...

（一）审议通过《关于<2024 年半年度报告>及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司 2024 年半年度报告的程序符 合法律、行政法规和中国证监会的规定，半年报内容真实、准确、完整地反映了 公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 证券代码：301101 证券简称：明月镜片 公告编号：2024-026 明月镜片股份有限公司 第二届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届监事会第十四次会议于 2024 年 8 月 20 日在公司会议室以现场表决方式召开。本次会议通知于 2024 年 8 月 9 日以专人送达、电话、微信等形式通知了全体监事。本次会议由监事会主 席朱海峰先生召集并主持，应出席公司会议的监事 3 人，实际出席公司会议的监 事 3 人。会议召开符合《中华人民共和国公司法》、《公司章程》等规定，会议合 法有效。 二、监事会会议审议情况 经与会监事充分讨论，本次会议审议通过议案如下： 经审核，监事会认为：公司本次部 ...

| 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2、督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | | | | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月查询一次 | | （2）公司募集资金项目进展是否与信息披 | 是 | | 露文件一致 | | | 4、公司治理督导情况 | | | （1）列席公司股东大会次数 | 0，均事前或事后审阅会议议案 | | （2）列席公司董事会次数 | 0，均事前或事后审阅会议议案 | 1 | （3）列席公司监事会次数 | 0，均事前或事后审阅会议议案 | | --- | --- | | 5、现场检查情况 | | | （1）现场检查次数 | ...

明月镜片股份有限公司 舆情管理制度 第一章 总 则 第一条 为提高明月镜片股份有限公司（以下简称"公司"）应对各类舆情 的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股价、 公司商业信誉及正常生产经营活动造成的影响，切实保护投资者和公司的合法权 益，根据《深圳证券交易所创业板股票上市规则》等相关法律法规的规定和《明 月镜片股份有限公司章程》（以下简称"《公司章程》"），结合公司实际情况， 特制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第七条 舆情信息采集范围应涵盖公司及控股子公司官网、微信公众号、抖 音官方账号、网络媒体、电子报、微信、微博、博客、互动易问答、论坛、贴吧、 股吧等各类型信息载体。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情（尤其是媒体质疑危机时）实行统一领导、统一 组织、快速反应、协同 ...

证券代码：301101 证券简称：明月镜片 公告编号：2024-025 明月镜片股份有限公司 第二届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届董事会第十四次会议于 2024 年 8 月 20 日在公司会议室以现场结合通讯的表决方式召开。本次会议通知于 2024 年 8 月 9 日以专人送达、电话、微信的方式通知了全体董事。本次会议由董事长谢 公晚先生主持，应出席会议董事 7 人，实际参加会议董事 7 人，公司监事、高级管 理人员列席会议。会议召开符合《中华人民共和国公司法》、《公司章程》等规定， 会议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<2024 年半年度报告>及其摘要的议案》； 公司董事会审计委员会已审议通过该议案。 表决结果：7 票同意；0 票反对；0 票弃权。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2024 年 半年度报告》及《2024 年半年度 ...